Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 14 of 15
Jan 26, 2026Accelerating progress in rare disease therapeutics demands innovative strategies beyond traditional frameworks. A sandbox approach that combines robust data analytics with regulatory experimentation offers a promising pathway to address inherent complexities and drive advancement in this difficult field.
Jan 24, 2026In the competitive landscape of narcolepsy treatments, Alkermes is pursuing strategic research and development to not only advance its orexin receptor-targeting drug Alixorexton but also to pave the way for innovative fatigue therapies, potentially transforming patient care beyond sleep disorders.
Jan 20, 2026A recent study analyzing diabetes management outcomes has provided compelling evidence that bariatric surgery delivers better control of type 2 diabetes than GLP-1 medications irrespective of patients’ income levels. This insight carries significant implications for the approach to diabetes care and healthcare policy.
Jan 15, 2026In the face of significant financial challenges impacting biomedical research, new data reveal a surprising uptick in graduate student enrollment in biomedical degree programs across the United States. This trend underscores the resilience and continued interest in the biomedical field, reflecting a potential shift in future research dynamics despite economic headwinds.
Jan 10, 2026Aktis Oncology’s public offering is set to strengthen its position in the radiopharmaceutical sector. The company’s novel approach with miniprotein-based radioconjugates promises potential benefits over existing targeted radiation therapies. Additionally, Aktis has established a discovery partnership with Eli Lilly to enhance its pipeline.
Jan 9, 2026Illumina named former NIH genomics director Eric Green as its Chief Medical Officer. His appointment comes as the company continues to push boundaries in genomics technologies and applications. Green’s experience is expected to enhance clinical strategy and innovation at Illumina.
Jan 9, 2026Building on the pioneering work of Baby KJ, this startup leverages both scientific breakthroughs and new FDA regulatory programs to accelerate development of personalized gene therapies utilizing CRISPR technology.
Jan 9, 2026Despite promises of a gene therapy delivery platform avoiding viral vectors, Rampart Bioscience is closing, highlighting ongoing challenges in gene therapy innovation and delivery technologies.
Jan 9, 2026The startup’s lead candidate is Phase 2-ready and hits the same dual targets as Amgen’s therapy but may offer better dosing benefits. Their pipeline also positions them against Roche and Novo Nordisk programs in development.
Jan 9, 2026Alveus Therapeutics recently secured $160 million to advance a Phase 2-ready drug tackling obesity through dual GLP-1 and GIP receptor modulation. The startup's approach may offer dosing advantages and compete with established pharma players like Amgen, Roche, and Novo Nordisk.
Jan 8, 2026After two successful Phase 3 studies, GSK's bepirovirsen demonstrates functional cure rates for chronic hepatitis B patients, potentially providing an alternative to lifelong antiviral regimens.
Jan 7, 2026GSK’s bepirovirsen achieved its primary endpoint in late-stage clinical trials, potentially offering an alternative to lifelong antiviral treatments for patients with chronic hepatitis B infection. This development marks a significant step toward a functional cure for the disease.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.